Allergan (NYSE: AGN) is a unique, global pharmaceutical company focused on developing, manufacturing and commercializing high quality generic and innovative branded pharmaceutical products for patients around the world.  The Company has approximately 30,000 employees worldwide and maintains global headquarters in Dublin, Ireland.

Kala Pharmaceuticals

Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its proprietary AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the August 2018 FDA approval of INVELTYS® for the treatment of inflammation and pain following ocular surgery and its lead product candidate, EYSUVIS® (KPI-121 0.25%), for the temporary relief of the signs and symptoms of dry eye disease. Kala recently reported positive Phase 3 results for EYSUVIS, which may enable a potential approval and launch by year-end 2020.

Novaliq Gmbh

Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free eye drop technology. Novaliq offers an industry-leading portfolio addressing today’s unmet needs of millions of patients with eye diseases. Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding gmbH & Co. KG, an active investor in Life and Health Sciences companies.

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives, starting with Demodex blepharitis. Tarsus was founded in 2017 and is headquartered in Irvine, California.


1:00 - 1:10 PM

Welcome and Dry Eye Overview

Presented By:
Paul Karpecki, OD, FAAO, Associate Professor - UPike College of Optometry/Kentucky Eye Institute

1:10 - 2:11 PM

Company Showcase

Novaliq GmbH | Sonja Krösser, PhD, VP, Preclinical & Clinical Development
AdOM Advanced Optical Technologies | Raanan Gefen, Managing Director
Kala Pharmaceuticals | Kim Brazzell, PhD, Chief Medical Officer
20/20 OptimEyes Technologies | Frances Lasowski, PhD, CEO
Tarsus Pharmaceuticals | Bobak Azamian, MD, PhD, CEO
Eyedetec Medical | Barry Linder, MD, President & CEO
Olympic Ophthalmics | Laura M Periman, MD , Founder and Director of Dry Eye Services & Clinical Research - Periman Eye Institute
Ocunova | Michael Shine, CEO

2:11 - 3:00 PM

The Dry Eye Outlook Panel


Whitney Hauser, OD, FAAO, Founder - Signal Ophthalmic Consulting
Marguerite McDonald, MD, FACS - OCLI (Ophthalmic Consultants of Long Island)
Joseph Tauber, MD, CEO - Tauber Eye Center
William Trattler, MD, President - Center for Excellence In Eye Care

Moderated By:
Paul Karpecki, OD, FAAO, Associate Professor - UPike College of Optometry/Kentucky Eye Institute

3:00 - 4:00 PM




Gain valuable exposure and visibility for your company's branding.


Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.


Connect and converse with nearly 5,000 innovative ophthalmic professionals.